Oxurion NV (OXUR) - Total Liabilities

Latest as of June 2025: €16.98 Million EUR ≈ $19.85 Million USD

Based on the latest financial reports, Oxurion NV (OXUR) has total liabilities worth €16.98 Million EUR (≈ $19.85 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Oxurion NV (OXUR) cash conversion ratio to assess how effectively this company generates cash.

Oxurion NV - Total Liabilities Trend (2006–2024)

This chart illustrates how Oxurion NV's total liabilities have evolved over time, based on quarterly financial data. Check Oxurion NV asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Oxurion NV Competitors by Total Liabilities

The table below lists competitors of Oxurion NV ranked by their total liabilities.

Company Country Total Liabilities
GO.D.M Investments Ltd
TA:GODM
Israel ILA165.00K
Exploitasi Energi Indonesia
JK:CNKO
Indonesia Rp2.15 Trillion
Rivalry Corp
V:RVLY
Canada CA$25.62 Million
Montfort Capital Corp
V:MONT
Canada CA$258.24 Million
GETT Gold Inc
V:GETT
Canada CA$18.53 Million
IO Biotech Inc
NASDAQ:IOBT
USA $39.05 Million
Cadence Minerals PLC
LSE:KDNC
UK GBX1.23 Million
SkinBioTherapeutics PLC
LSE:SBTX
UK GBX2.71 Million

Liability Composition Analysis (2006–2024)

This chart breaks down Oxurion NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OXUR market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.17 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.41 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oxurion NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oxurion NV (2006–2024)

The table below shows the annual total liabilities of Oxurion NV from 2006 to 2024.

Year Total Liabilities Change
2024-12-31 €16.75 Million
≈ $19.59 Million
-15.11%
2023-12-31 €19.74 Million
≈ $23.07 Million
+19.06%
2022-12-31 €16.58 Million
≈ $19.38 Million
-17.05%
2021-12-31 €19.98 Million
≈ $23.36 Million
+116.37%
2020-12-31 €9.24 Million
≈ $10.80 Million
-21.22%
2019-12-31 €11.72 Million
≈ $13.71 Million
+22.71%
2018-12-31 €9.55 Million
≈ $11.17 Million
-44.06%
2017-12-31 €17.08 Million
≈ $19.97 Million
+45.03%
2016-12-31 €11.78 Million
≈ $13.77 Million
+31.87%
2015-12-31 €8.93 Million
≈ $10.44 Million
-29.69%
2014-12-31 €12.70 Million
≈ $14.85 Million
+2.58%
2013-12-31 €12.38 Million
≈ $14.48 Million
+10.50%
2012-12-31 €11.21 Million
≈ $13.10 Million
+1.31%
2011-12-31 €11.06 Million
≈ $12.93 Million
+132.99%
2010-12-31 €4.75 Million
≈ $5.55 Million
-36.72%
2009-12-31 €7.50 Million
≈ $8.77 Million
+55.95%
2008-12-31 €4.81 Million
≈ $5.62 Million
+35.04%
2007-12-31 €3.56 Million
≈ $4.16 Million
+73.25%
2006-12-31 €2.06 Million
≈ $2.40 Million
--

About Oxurion NV

BR:OXUR Belgium Biotechnology
Market Cap
$311.42K
€266.37K EUR
Market Cap Rank
#30706 Global
#113 in Belgium
Share Price
€0.00
Change (1 day)
+0.00%
52-Week Range
€0.00 - €0.07
All Time High
€102000.00
About

Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more